Please enable JavaScript to continue using this application.

Compare $ALDX vs $XLO | Chartloom

Compare

$ALDX vs $XLO

Aldeyra Therapeutics Inc · Xilio Therapeutics Inc

ALDX

Aldeyra Therapeutics Inc

XLO

Xilio Therapeutics Inc

Compare $ALDX vs $XLO

Comparing Aldeyra Therapeutics Inc and Xilio Therapeutics Inc

ALDXAldeyra Therapeutics Inc

XLOXilio Therapeutics Inc

ALDXAldeyra Therapeutics Inc

Market cap

$55M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

—

Rev growth (TTM)

—

YTD performance

-80.4%

52W performance

-83.7%

FCF yield

-39.9%

XLOXilio Therapeutics Inc

Market cap

$54M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

3.42x

Rev growth (TTM)

327.3%

YTD performance

-3.8%

52W performance

-23.1%

FCF yield

-113.2%

Add ticker

Add up to 1 more ticker to compare

Relative performance

Each ticker starts at 100. 110 means +10% from the start of this window — not a $110 share price.

ALDX

XLO

Detailed metrics comparison

ALDX

Aldeyra Therapeutics Inc

XLO

Xilio Therapeutics Inc

Market Cap

ALDX$55M

XLO$54M

Enterprise Value

ALDX$10M

XLO$-82M

Price

ALDX$0.92

XLO$9.05

P/E Ratio

ALDXN/A

XLON/A

P/S Ratio

ALDX0.00x

XLO0.84x

EV/Sales

ALDX0.00x

XLO-1.28x

EV/EBITDA

ALDX0.00x

XLO0.00x

P/B Ratio

ALDX1.86x

XLO0.82x

P/FCF Ratio

ALDXN/A

XLON/A

EV/FCF

ALDX-0.46x

XLO1.34x

PEG Ratio

ALDXN/A

XLON/A

Forward P/E (NTM)

ALDXN/A

XLON/A

Forward P/S (NTM)

ALDXN/A

XLO3.42x

Revenue (TTM)

ALDX$0

XLO$64M

Revenue Growth (YoY)

ALDXN/A

XLO327.3%

Forward Rev Growth

ALDX298.2%

XLO-34.2%

Gross Margin (TTM)

ALDX0.0%

XLO0.0%

Operating Margin (TTM)

ALDX0.0%

XLO0.0%

EBITDA Margin (TTM)

ALDX0.0%

XLO-46.9%

Net Margin (TTM)

ALDX0.0%

XLO-34.1%

FCF Margin (TTM)

ALDXN/A

XLO-95.6%

Net Income (TTM)

ALDX$-23M

XLO$-22M

FCF (TTM)

ALDX$-22M

XLO$-61M

EPS (TTM)

ALDX-$0.38

XLO-$1.12

ROE (TTM)

ALDX-5314.0%

XLO-923.0%

ROA (TTM)

ALDX-3494.0%

XLO-1441.0%

ROIC (TTM)

ALDX-4205.0%

XLO-923.0%

Cash

ALDX$45M

XLO$136M

Debt

ALDX$0

XLO$0

Net Cash/Debt

ALDX$45M

XLO$136M

Current Ratio (TTM)

ALDX4.91x

XLO4.25x

Quick Ratio (TTM)

ALDX4.74x

XLO4.15x

Debt/Equity (TTM)

ALDX0.34x

XLO0.00x

Debt/Assets (TTM)

ALDX0.0%

XLO0.0%

Interest Coverage (TTM)

ALDXN/A

XLON/A

Net Debt/EBITDA (TTM)

ALDX0.00x

XLO0.00x

Beta

ALDX1.21

XLO-0.12

52W Performance

ALDX-83.7%

XLO-23.1%

YTD Performance

ALDX-80.4%

XLO-3.8%

% from 52W High

ALDX-84.5%

XLO-28.1%

% from 52W Low

ALDX6.3%

XLO40.0%

Asset Turnover (TTM)

ALDX0.00x

XLO0.42x

FCF Yield (TTM)

ALDX-39.9%

XLO-113.2%

Earnings Yield (TTM)

ALDX-41.7%

XLO-40.3%

Dividend Yield (TTM)

ALDXN/A

XLON/A

Rule of 40

ALDX0.0

XLO231.7

EV/GP/RG

ALDXN/A

XLON/A

Ticker research

View ALDX research View XLO research

Metric	ALDX Aldeyra Therapeutics Inc	XLO Xilio Therapeutics Inc
Market & Valuation
Market Cap	$55M	$54M
Enterprise Value	$10M	$-82M
Price	$0.92	$9.05
P/E Ratio	N/A	N/A
P/S Ratio	0.00x	0.84x
EV/Sales	0.00x	-1.28x
EV/EBITDA	0.00x	0.00x
P/B Ratio	1.86x	0.82x
P/FCF Ratio	N/A	N/A
EV/FCF	-0.46x	1.34x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	N/A	3.42x
Revenue & Growth
Revenue (TTM)	$0	$64M
Revenue Growth (YoY)	N/A	327.3%
Forward Rev Growth	298.2%	-34.2%
Profitability
Gross Margin (TTM)	0.0%	0.0%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	0.0%	-46.9%
Net Margin (TTM)	0.0%	-34.1%
FCF Margin (TTM)	N/A	-95.6%
Net Income (TTM)	$-23M	$-22M
FCF (TTM)	$-22M	$-61M
EPS (TTM)	-$0.38	-$1.12
ROE (TTM)	-5314.0%	-923.0%
ROA (TTM)	-3494.0%	-1441.0%
ROIC (TTM)	-4205.0%	-923.0%
Financial Health
Cash	$45M	$136M
Debt	$0	$0
Net Cash/Debt	$45M	$136M
Current Ratio (TTM)	4.91x	4.25x
Quick Ratio (TTM)	4.74x	4.15x
Debt/Equity (TTM)	0.34x	0.00x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	1.21	-0.12
52W Performance	-83.7%	-23.1%
YTD Performance	-80.4%	-3.8%
% from 52W High	-84.5%	-28.1%
% from 52W Low	6.3%	40.0%
Efficiency & Yields
Asset Turnover (TTM)	0.00x	0.42x
FCF Yield (TTM)	-39.9%	-113.2%
Earnings Yield (TTM)	-41.7%	-40.3%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	0.0	231.7
EV/GP/RG	N/A	N/A
Ticker research	View ALDX research	View XLO research

Valuation

P/S Ratio

ALDX

0.00x

XLO

0.84x

EV/FCF

ALDX

-0.46x

XLO

1.34x

Growth & revenue

Revenue Growth TTM

XLO

327.3%

Forward Revenue Growth

ALDX

298.2%

XLO

-34.2%

Profitability & performance

Gross Margin

ALDX

0.0%

XLO

0.0%

ROE

XLO

-923.0%

ALDX

-5314.0%

FCF Yield %

ALDX

-39.9%

XLO

-113.2%

52-Week Performance

XLO

-23.1%

ALDX

-83.7%

Detailed metrics comparison

ALDX

Aldeyra Therapeutics Inc

XLO

Xilio Therapeutics Inc

Market Cap

ALDX$55M

XLO$54M

Enterprise Value

ALDX$10M

XLO$-82M

Price

ALDX$0.92

XLO$9.05

P/E Ratio

ALDXN/A

XLON/A

P/S Ratio

ALDX0.00x

XLO0.84x

EV/Sales

ALDX0.00x

XLO-1.28x

EV/EBITDA

ALDX0.00x

XLO0.00x

P/B Ratio

ALDX1.86x

XLO0.82x

P/FCF Ratio

ALDXN/A

XLON/A

EV/FCF

ALDX-0.46x

XLO1.34x

PEG Ratio

ALDXN/A

XLON/A

Forward P/E (NTM)

ALDXN/A

XLON/A

Forward P/S (NTM)

ALDXN/A

XLO3.42x

Revenue (TTM)

ALDX$0

XLO$64M

Revenue Growth (YoY)

ALDXN/A

XLO327.3%

Forward Rev Growth

ALDX298.2%

XLO-34.2%

Gross Margin (TTM)

ALDX0.0%

XLO0.0%

Operating Margin (TTM)

ALDX0.0%

XLO0.0%

EBITDA Margin (TTM)

ALDX0.0%

XLO-46.9%

Net Margin (TTM)

ALDX0.0%

XLO-34.1%

FCF Margin (TTM)

ALDXN/A

XLO-95.6%

Net Income (TTM)

ALDX$-23M

XLO$-22M

FCF (TTM)

ALDX$-22M

XLO$-61M

EPS (TTM)

ALDX-$0.38

XLO-$1.12

ROE (TTM)

ALDX-5314.0%

XLO-923.0%

ROA (TTM)

ALDX-3494.0%

XLO-1441.0%

ROIC (TTM)

ALDX-4205.0%

XLO-923.0%

Cash

ALDX$45M

XLO$136M

Debt

ALDX$0

XLO$0

Net Cash/Debt

ALDX$45M

XLO$136M

Current Ratio (TTM)

ALDX4.91x

XLO4.25x

Quick Ratio (TTM)

ALDX4.74x

XLO4.15x

Debt/Equity (TTM)

ALDX0.34x

XLO0.00x

Debt/Assets (TTM)

ALDX0.0%

XLO0.0%

Interest Coverage (TTM)

ALDXN/A

XLON/A

Net Debt/EBITDA (TTM)

ALDX0.00x

XLO0.00x

Beta

ALDX1.21

XLO-0.12

52W Performance

ALDX-83.7%

XLO-23.1%

YTD Performance

ALDX-80.4%

XLO-3.8%

% from 52W High

ALDX-84.5%

XLO-28.1%

% from 52W Low

ALDX6.3%

XLO40.0%

Asset Turnover (TTM)

ALDX0.00x

XLO0.42x

FCF Yield (TTM)

ALDX-39.9%

XLO-113.2%

Earnings Yield (TTM)

ALDX-41.7%

XLO-40.3%

Dividend Yield (TTM)

ALDXN/A

XLON/A

Rule of 40

ALDX0.0

XLO231.7

EV/GP/RG

ALDXN/A

XLON/A

Ticker research

View ALDX research View XLO research

Metric	ALDX Aldeyra Therapeutics Inc	XLO Xilio Therapeutics Inc
Market & Valuation
Market Cap	$55M	$54M
Enterprise Value	$10M	$-82M
Price	$0.92	$9.05
P/E Ratio	N/A	N/A
P/S Ratio	0.00x	0.84x
EV/Sales	0.00x	-1.28x
EV/EBITDA	0.00x	0.00x
P/B Ratio	1.86x	0.82x
P/FCF Ratio	N/A	N/A
EV/FCF	-0.46x	1.34x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	N/A	3.42x
Revenue & Growth
Revenue (TTM)	$0	$64M
Revenue Growth (YoY)	N/A	327.3%
Forward Rev Growth	298.2%	-34.2%
Profitability
Gross Margin (TTM)	0.0%	0.0%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	0.0%	-46.9%
Net Margin (TTM)	0.0%	-34.1%
FCF Margin (TTM)	N/A	-95.6%
Net Income (TTM)	$-23M	$-22M
FCF (TTM)	$-22M	$-61M
EPS (TTM)	-$0.38	-$1.12
ROE (TTM)	-5314.0%	-923.0%
ROA (TTM)	-3494.0%	-1441.0%
ROIC (TTM)	-4205.0%	-923.0%
Financial Health
Cash	$45M	$136M
Debt	$0	$0
Net Cash/Debt	$45M	$136M
Current Ratio (TTM)	4.91x	4.25x
Quick Ratio (TTM)	4.74x	4.15x
Debt/Equity (TTM)	0.34x	0.00x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	1.21	-0.12
52W Performance	-83.7%	-23.1%
YTD Performance	-80.4%	-3.8%
% from 52W High	-84.5%	-28.1%
% from 52W Low	6.3%	40.0%
Efficiency & Yields
Asset Turnover (TTM)	0.00x	0.42x
FCF Yield (TTM)	-39.9%	-113.2%
Earnings Yield (TTM)	-41.7%	-40.3%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	0.0	231.7
EV/GP/RG	N/A	N/A
Ticker research	View ALDX research	View XLO research